Accuray Incorporated (NASDAQ:ARAY) shares increased 2.60% in last trading session and ended the day at $5.52. ARAY Gross Margin is 38.30% and its has a return on assets of -8.70%. Accuray Incorporated (NASDAQ:ARAY) quarterly performance is -18.10%.
Accuray Incorporated (NASDAQ: ARAY) will report results for its fiscal first quarter ended September 30, 2015 on October 29, 2015 after the market close. Management will host a conference call to review the results at 1:30 p.m. PT/4:30 p.m. ET on the same day.
Yahoo! Inc. (NASDAQ:YHOO) ended the last trading day at $33.37. Company weekly volatility is calculated as 2.15% and price to cash ratio as 5.39. Yahoo! Inc. (NASDAQ:YHOO) showed a weekly performance of 2.61%.
In a press release today, Yahoo! Inc. (NASDAQ:YHOO) has announced the launch of a new Yahoo Mail app as part of the company’s 18th anniversary celebration. The latest app, which is more intuitive, faster and well-designed, is updated with several new features such as rich compose and smarter search, and these will be available to both iOS and Android users. Yahoo Account Key is one of the major additions to this app.
On 16 October, Sony Corp (ADR) (NYSE:SNE) shares advanced 0.70% and was closed at $27.18. SNE EPS growth in last 5 year was -22.60%. Sony Corp (ADR) (NYSE:SNE) year to date (YTD) performance is 32.78%.
Sony Corp (ADR) (NYSE:SNE) said it will cut prices of PlayStation 4 in the U.S. and Canada as it attempts to further bolster sales of the popular videogame console.The new prices, which will take effect on Friday, are $349.99 in the U.S. and C$429.99 ($329.34) in Canada. They are currently sold for $399.99 and C$449.99, respectively. By cutting the price at this time, we aim to fuel momentum of PlayStation 4 toward the year-end holiday season,” a spokesman at Sony Computer Entertainment Inc., the group’s videogame arm, said.
Puma Biotechnology, Inc. (NYSE:PBYI) shares increased 0.78% in last trading session and ended the day at $82.91. And its has a return on assets of -82.70%. Puma Biotechnology, Inc. (NYSE:PBYI) quarterly performance is -19.71%.
Puma Biotechnology, Inc. (PBYI), announced the presentation of positive results from the Phase III clinical trial of Puma’s investigational drug PB272 (neratinib) for the extended adjuvant treatment of breast cancer (ExteNET trial) in patients with centrally confirmed HER2-positive early stage breast cancer. The ExteNET trial is a double-blind, placebo-controlled, Phase III trial of neratinib versus placebo after adjuvant treatment with trastuzumab (Herceptin) in women with early stage HER2-positive breast cancer. The data was presented today in an oral presentation at the American Society of Clinical Oncology (ASCO) 2015 Breast Cancer Symposium in San Francisco, California. This data was previously presented in June at the ASCO Annual Meeting in Chicago, Illinois.
Loxo Oncology, Inc. (NASDAQ:LOXO) caters to the Healthcare space. Its weekly performance is 14.36%. On the last day of trading company shares ended up at $24.21. Loxo Oncology, Inc. (NASDAQ:LOXO) distance from 50-day simple moving average (SMA50) is 19.12%.
Loxo Oncology (NASDAQ:LOXO) was upgraded by Zacks from a “sell” rating to a “hold” rating in a report released on Friday.
Leave a Reply